Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.

  • Partnership with CannFX, New Zealand's leading cannabis supplier, is a strong addition to the Cantourage platform, which supplies medical cannabis to wholesalers and pharmacies throughout Europe
  • CannFX's non-irradiated dried flowers is the first New Zealand medical cannabis product to be made available in Germany, with CannFX's 'Wappa' strain now available in pharmacies across Germany
  • CannFX has signed agreements with multiple cultivators in New Zealand to provide high quality non-irradiated dried cannabis flowers to global markets

Berlin, 29. November 2022 - Cantourage Group SE (FRA: HIGH), a European medical cannabis leader has formed a partnership with New Zealand's leading medical cannabis supplier, CannFX, to bring medical cannabis from New Zealand to Germany for the first time. From today, pharmacies and patients throughout Germany will have access to CannFX's first THC cultivar "Wappa". Cantourage plans to also make the products available in additional European markets, including the UK, in 2023.

CannFX was founded in 2019, with the vision to bring the benefits of New Zealand grown medical cannabis to patients globally. The company has signed agreements with cultivators in New Zealand to supply global markets with high-quality dried cannabis flowers. The product being released is the first of multiple strains that CannFX will make available together with Cantourage for the EU and UK markets.

Philip Schetter, CEO of Cantourage, says: "We are excited about our partnership with CannFX. By integrating CannFX's products into our platform, we are delivering on our commitment to bring medical cannabis from across the world to Europe, thereby offering even more treatment choices to patients."

Bastiaan Kramer, CEO of CannFX, comments: "We feel privileged to be the first company to bring New Zealand medical cannabis products to patients and pharmacies in Europe, thanks to our collaboration with Cantourage. This represents an expansion of our global reach and at the same time, strengthens our commitment to New Zealand's cannabis industry. The EU and the UK are important and rapid expanding markets, and we look forward to playing a role in meeting the needs of a growing number of patients."

About Cantourage

Cantourage is a publicly listed, leading European medical cannabis company. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffman. Cantourage enables producers from all over the world to become part of the rapidly growing European medical cannabis market in a faster and more cost-effective way, while guaranteeing and developing the highest European quality standards. The company offers products in all relevant market segments: dried flowers, extracts, Dronabinol and pharma-grade Cannabidiol. The company was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under the stock ticker "HIGH".

About CannFX

CannFX was founded in 2019 and is the brand that represents the majority of New Zealand's medical cannabis cultivators. The company has signed agreements with only the best cultivators in New Zealand to consistently grow, produce, and distribute the cleanest and highest-grade non-irradiated medical cannabis flower. New Zealand has set the most stringent quality standards in the world for the export of non-irradiated medical cannabis. CannFX is actively working to meet and exceed these standards so that patients benefit from the highest quality dried flower available on the market. Learn more:

This announcement does not constitute a public offer or an advertisement for a public offer within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company's financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.

In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as "Relevant Persons"). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.

Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.